Advertisement

Topics

Latest "BioTech Capital Limited" News Stories

19:05 EST 19th February 2018 | BioPortfolio

Here are the most relevant search results for "BioTech Capital Limited" found in our extensive news archives from over 250 global news sources.

More Information about BioTech Capital Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about BioTech Capital Limited for you to read. Along with our medical data and news we also list BioTech Capital Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioTech Capital Limited Companies for you to search.

Showing "BioTech Capital Limited" News Articles 1–25 of 10,000+

Relevant

Where is the Money Going in Biotech? A Peek into European VC Strategy

Hubert Birner, Managing Partner at TVM Capital Life Science, discusses his strategy to adapt to the European funding constraints and the areas with most potential for biotech investment. TVM Capital Life Science is a venture capital firm focusing on biotech, ... This awesome article Where is the Money Going in Biotech? A Peek into European VC Strategy appeared first on Labiotech.eu. Be kind and do...


New Venture Fund Closes $102M to Boost Biotech and Medical Device Development

Truffle Capital has raised $102M (€85M), which will be used to support biotech and medical device companies that have the potential to become market leaders. Truffle Capital, founded in 2001 and based in Paris, is a venture capital firm that ... This awesome article New Venture Fund Closes $102M to Boost Biotech and Medical Device Development appeared first on Labiotech.eu. Be kind and don't cop...

Will Biotech Continue To Boom?

Biotechs have surged in 2017 - how much higher can they fly?Avisol Capital Partners joins the Roundtable to discuss their approach to biotech valuations and the warning signs they look for in the stocks they research.They also opine on Celyad and CAR-T, and the near-term future of the biotech sector as a whole.


eG Capital: Australian Biotech: A 2007 Perspective from Alison Coutts

In this exclusive interview, Fintan Walton talks to Alison Coutts, Executive Director at eG Capital in Sydney, Australia. Alison reviews some of the major changes she has observed in the biotech and pharmaceutical industry in Australia over the last 12 months, reflecting on the progress that many companies have made and the general maturation of the industry as a whole. She discusses the increasin...

Aisling Capital: Investment Strategies and How to Revive Biotech

In this episode of PharmaTelevision News Review, Fintan Walton talks with Dennis Purcell at Aisling Capital. Filmed at Bio-Europe Spring 2010 in Barcelona, Spain, they discuss: • Dennis' history in the biotech sector • Key changes to biotech business models in the last 30 years • Aisling's investment strategy • How the company raised US $650M in January 2009, and how that fund is being ...

Acticor Biotech Announces the Closing of a 1.7 Million Equity Financing Led by Primer Capital

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announces today the closing of an equity financing led by Primer Capital. The financing round includes investments in equity from Primer Capital and historical shareholders - Anaxago, CapDecisif Management - and private...

Sartorius Stedim Biotech SA: Disclosure of Share Capital and Voting Rights

Dow Jones received a payment from EQS/DGAP to publish this press release. Sartorius Stedim Biotech SA: Disclosure of Share Capital and Voting Rights 04-Dec-2017 / 08:45 CET/CEST Dissemination of a...

MPM Capital: The Perfect Storm in Healthcare

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Vaughn Kailian, Managing Director at MPM Capital, one of the world's largest life science-dedicated venture investors. They discuss: • why 2009 has been a landmark year for the biotech industry • survival in the current financial crisis • healthcare reform and the politcs involved • how the best ideas wil...

Beck Capital Management LLC Boosts Stake in SPDR S&P Biotech Etf

Beck Capital Management LLC grew its stake in shares of SPDR S&P Biotech ETF by 235.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 63,899 shares of the exchange traded fund's stock after acquiring an additional 44,866 shares during the period.

TVM Capital: Investment Strategies, Relationships with Big Pharma and Biotech Financing

In this episode of PharmaTelevision News Review, Fintan Walton talks with Dr Axel Polack, General Partner at TVM Capital. Filmed at BioBusiness 2010 in London, England, they discuss: • TVM’s investment strategy • Platform companies • The effects of the economic crisis • Milestones, exit strategies and the lack of an IPO market • Relationships with big Pharma • Financing in the biotec...

Financial Partners Capital Management LLC Has $6.02 Million Position in SPDR S&P Biotech Etf

Financial Partners Capital Management LLC lowered its stake in shares of SPDR S&P Biotech ETF by 2.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The institutional investor owned 69,566 shares of the exchange traded fund's stock after selling 2,025 shares during the quarter.

China commits US$1.3b in venture funds for British biotech firms

Future Planet Capital and Eight Great Technologies will invest the funds in Britain's most innovative biotech, medicine and life sciences companies China's increasing zeal for improving biotechnology and medical services is music to the ears of the British government after two venture capital firms received 8 billion yuan in funding commitments from mainland investors during Prime Minister...

Correction to company release dated January 26, 2018 - Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - number of shares

FIT Biotech Oy Company release January 29, 2018 at 11:35 AM EET Correction to company release dated January 26, 2018 - Conversion of FIT Biotech Oy's Convertible Capital Notes into shares - number of shares Due to the conversion of the Convertible Capital Notes, the Company transfers 20,000,000 K shares owned by the Company to ABO.  On company release January 26, 2018, the...

Orchard Therapeutics Scoops Up $110M in Funding Round

Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund.

FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares

FIT Biotech Oy Company release October 5, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 between the FIT Biotech Oy ("Company") and Bracknor Investment ("Bracknor") the Company's board of directors have  resolved on October 4, ...

Flagship Pioneering Announces Capital Raise of $618M

NewsThe addition to Flagship's capital base comes on the heels of a year of record growth for the firm and its portfolio companies.Contributed Author:&nb

Orchard Therapeutics Scoops Up $110M in Funding to Advance "Bubble Boy Syndrome" Gene Therapy

Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund.

Aisling Capital Closes $280M Fund to Improve Global Health

NewsAisling Capital will assist companies developing therapeutics to complete their clinical studies, navigate approval and ultimately reach commercialization.

Meet the Experts: Discussion on Early-Stage Financing of Biotech Companies in Europe

Fintan Walton leads our panel of industry experts in an in-depth discussion about the early-stage financing of biotech companies in Europe. With viewpoints from both financial and biotech companies, our panellists provide a refreshing perspective on the current issues that face would-be CEOs, trying to secure seed capital in Europe's biotech start-up arena.

STAT Plus: 3 women in biotech finance to watch in 2018

Meet three women who have pushed to diversify the clubby venture capital world of Silicon Valley and are fighting to advance more women's careers in biotech and health care.

Paul Capital Partners: Growth Capital Providers for the Biotech Industry

In this interview, filmed during the recent BIO conference in San Diego, Fintan Walton speaks with Ken Macleod, partner in the well-known Paul Capital Partners, located in London. He tells how the company differs from traditional venture capitalist funds by providing funding based on royalty interests and revenue interests. Using these methods, Paul Capital is able to provide non-dilutive funding ...

Acticor Biotech Announces the Closing of a €1.7 Million Equity Financing Led by Primer Capital

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including stroke and other thrombosis disorders like pulmonary embolism, announces today the closing of an equity financing led by Primer Capital. The financing round includes investments in equity from Primer Capital and historical shareholders - An...

Engine Biosciences Lands $10M for AI-Driven Drug Discovery Platform

Engine Biosciences(“Engine”), a San Francisco, CA-based biotech company pioneering its artificial intelligence and genomics network biomedicine platform for drug discovery has raised $10 million. The seed round was co-led by by DHVC (Danhua Capital) and 6 Dimensions Capital, with participation from global biopharmaceutical leader WuXi AppTec, EDBI, Pavilion Capital, Baidu Ventures, WI ...

Aisling Capital: How Funding Must Adapt to the Current Market

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with Dennis Purcell, Senior Managing Partner at Aisling Capital, an investment company dedicated to funding global healthcare companies. They discuss: • Dennis' experiences of the market's booms and slumps • how funding has had to adapt • bankruptcies and efficiency of capital • how the funding model will chan...

Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL

Dow Jones received a payment from EQS/DGAP to publish this press release. Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL 0...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks